Mikhail Blagosklonny Offers Modern Cancer Treatment through Target of Rapamycin

Mikhail Blagosklonny is a research scientist. He specializes in cancer research with the aim of finding treatment through therapies. For decades, cancer has been cited as one of the world’s leading problems in the medical sector. With the focus to fight the rising numbers of cancer patients, Mikhail has progressively made enormous contributions towards the […]... Read More

Clay Siegall: The Brain Behind Cancer-Based Genetic Research

In January 2013, Mirna Therapeutics appointed the chairperson and present CEO of Seattle Genetics, Clay Siegall to its long list of Board of Directors as an outside director. The rich cancer research history that Clay possesses was seen as the main driving force towards his appointment by Mirna Therapeutics CEO, DR. Paul Lammers. Though both […]... Read More

Seattle based biotech company, Seattle Genetics, receives largest round of funding yet

In just one week this September, the public stock offering of Seattle Genetics, a biotechnology firm based in Bothell, increased from $480 million to $552 million. The company exercised its over-allotment option, as it started getting a lot more attention from investors. The CEO of the company, Clay Siegall, announced that the money will be […]... Read More

Seattle Genetics’ Leadership in the Development of Antibody-Drug Conjugates

Seattle Genetics, a biotechnology company, has established a reputation for itself as a global leader in the development of antibody-drug conjugates (ADCs).The ADC technology is designed to take up or imitate the targeting capabilities possessed by monoclonal antibodies in delivering killing agents to cancer cells directly. Though other engineered antibodies lack adequate inherent antitumor activity to be utilized as therapeutics, Seattle Genetics has come up with revolutionary technology that has propelled the next level in the development of antibody-based therapeutic therapies. Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript ADCETRIS (brentuximab vedotin) represents one of the top ADCs from Seattle Genetics, which was developed in close partnership with Takeda Pharmaceutical Company. Currently, the ADC is commercially present in over 65 nations such as members of the European Union, Japan, Canada and the United States. Through its proprietary technology, the company hopes to continue promoting its ADC development and currently boasts of over 20 ADCs in clinical development. It boasts of strategic collaborations with other companies such as Progenics, Medlmmune, Genentech, Bayer and CuraGen. Seattle Genetics’ dominance in the industry is credited to its leadership team, which is led by Dr. Clay Siegall. Clay Siegall Clay Siegall is highly recognized as the co-founder, President as well as Chief Executive Officer of Seattle Genetics. He is not only an alumnus of the University of Maryland where he earned a B.S.in Zoology but also a Ph.D. holder in Genetics, which he received from the George Washington University. His level of experience can be tracked from roles in other companies and institutions such as National Institutes of Health, the National Cancer Institute, and the Bristol-Myers Squibb Pharmaceutical Research Institute. Clay is also a board member of various biotechnology companies such as Mirna Therapeutics as well as Alder Biopharmaceuticals. His instrumental leadership at Seattle Genetics has helped the biotechnology company secure numerous licenses for its antibody-drug conjugates technology with entities such as Pfizer, GlaxoSmithKline, AbbVie, and Genentech. Through these strategic licenses, Seattle Genetics has generated over $300 million in revenue. He is also credited for leading the company’s capital-raising initiatives, which has yielded into securing over $675 million consisting of both private and public funding.... Read More